Risankizumab for Crohn's disease
- PMID: 35644143
- DOI: 10.1016/S0140-6736(22)00628-6
Risankizumab for Crohn's disease
Conflict of interest statement
I declare consultancy fees from Apo Puls Station, AbbVie GK, Bristol-Myers Squibb, EA Pharma, Eli Lilly, Gilead Sciences, Janssen, Mitsubishi-Tanabe Pharma, Nichi-Iko Pharmaceutical, Pfizer, Takeda Pharmaceutical, and Zeria Pharmaceutical, and lecture fees from AbbVie GK, Ferring, Gilead Sciences, Janssen, JIMRO, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutical, Pfizer, Sandoz KK, and Takeda Pharmaceutical, all outside the area of work commented on here.
Comment on
-
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
-
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4. Lancet. 2022. PMID: 35644155 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical